Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer
The aim of this cross-sectional study is to evaluate the factors associated with patient-reported dysphagia in patients affected by locally advanced oropharyngeal cancer (OPC) treated with definitive intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy (CHT), with or without induction CHT. We evaluated 148 OPC patients treated with IMRT and concurrent CHT, without evidence of disease and who had completed their treatment since at least 6 months. At their planned follow-up visit, patients underwent clinical evaluation and completed the M.D. Anderson dysphagia inventory (MDADI) questionnaire. The association between questionnaire composite score (MDADI-CS) and different patients’ and tumor’s characteristics and treatments (covariates) was investigated by univariable and multivariable analyses, the latter including only covariates significant at univariable analysis. With a median time from treatment end of 30 months [range 6–74 months, interquartile range (IQR) 16–50 months], the median (IQR) MDADI-CS was 72 (63–84). The majority of patients (82.4%) had a MDADI-CS ≥ 60. At multivariable analysis, female gender, human papilloma virus (HPV)-negative status, and moderate and severe clinician-rated xerostomia were significantly associated with lower MDADI-CS. Patient-perceived dysphagia was satisfactory or acceptable in the majority of patients. HPV status and xerostomia were confirmed as important predictive factors for swallowing dysfunction after radiochemotherapy. Data regarding female gender are new and deserve further investigation.
KeywordsOropharyngeal carcinoma Long-term dysphagia MDADI score Human papilloma virus Xerostomia
Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, PhD, Ambra Corti, and Sara Parodi, PhD; this assistance was supported by internal funds.
No funding was received for the preparation of this manuscript.
Compliance with Ethical Standards
Conflict of interest
The Authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, Magnuson JS, Spencer SA, Bonner JA. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;73:410–5. https://doi.org/10.1016/j.ijrobp.2008.04.048.CrossRefGoogle Scholar
- 3.Russi EG, Corvò R, Merlotti A, Alterio D, Franco P, Pergolizzi S, De Sanctis V, Ruo Redda MG, Ricardi U, Paiar F, Bonomo P, Merlano MC, Zurlo V, Chiesa F, Sanguineti G, Bernier J. Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treat Rev. 2012;38:1033–49. https://doi.org/10.1016/j.ctrv.2012.04.002.CrossRefGoogle Scholar
- 4.Nguyen NP, Moltz CC, Frank C, Vos P, Smith HJ, Karlsson U, Nguyen LM, Rose S, Dutta S, Sallah S. Evolution of chronic dysphagia following treatment for head and neck cancer. Oral Oncol. 2006;42:374–80. https://doi.org/10.1016/j.oraloncology.2005.09.003.CrossRefGoogle Scholar
- 5.Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770–6. https://doi.org/10.1200/JCO.2007.14.6647.CrossRefGoogle Scholar
- 6.Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA, Cornwall B, Lee CSY, Chepeha DB, Eisbruch A. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013;85:935–40. https://doi.org/10.1016/j.ijrobp.2012.08.030.CrossRefGoogle Scholar
- 7.Al-Mamgani A, Mehilal R, van Rooij PH, Tans L, Sewnaik A, Levendag PC. Toxicity, quality of life, and functional outcomes of 176 hypopharyngeal cancer patients treated by (chemo)radiation: the impact of treatment modality and radiation technique. Laryngoscope. 2012;122:1789–95. https://doi.org/10.1002/lary.23387.CrossRefGoogle Scholar
- 8.Ramaekers BL, Joore MA, Grutters JP, van den Ende P, Jong Jd, Houben R, Lambin P, Christianen M, Beetz I, Pijls-Johannesma M, Langendijk JA. The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncol. 2011;47:768–74. https://doi.org/10.1016/j.oraloncology.2011.05.012.CrossRefGoogle Scholar
- 9.Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010;28:2732–8. https://doi.org/10.1200/JCO.2009.24.6199.CrossRefGoogle Scholar
- 10.Eisbruch A, Kim HM, Feng FY, Haxer MJ, Feng M, Worden FP, Bradford CR, Prince ME, Moyer JS, Wolf GT, Chepeha DB, Ten Haken RK. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys. 2011;81:e93–9. https://doi.org/10.1016/j.ijrobp.2010.12.067.CrossRefGoogle Scholar
- 13.Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, Dutilh J, Fulton JS, Jankovic L, Lopes NN, Mello AL, Muniz LV, Murdoch-Kinch CA, Nair RG, Napeñas JJ, Nogueira-Rodrigues A, Saunders D, Stirling B, von Bültzingslöwen I, Weikel DS, Elting LS, Spijkervet FK, Brennan MT, Salivary Gland Hypofunction/Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18:1039–60.CrossRefGoogle Scholar
- 14.Pedersen A, Wilson J, McColl E, Carding P, Patterson J. Swallowing outcome measures in head and neck cancer–How do they compare? Oral Oncol. 2016;52:104–8. https://doi.org/10.1016/j.oraloncology.2015.10.015.CrossRefGoogle Scholar
- 16.Goepfert RP, Lewin JS, Barrow MP, Gunn GB, Fuller CD, Beadle BM, Garden AS, Rosenthal DI, Kies MS, Papadimitrakopoulou V, Lai SY, Gross ND, Schwartz DL, Hutcheson KA. Long-term, prospective performance of the MD Anderson dysphagia inventory in “Low-Intermediate Risk” oropharyngeal carcinoma after intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2017;97:700–8. https://doi.org/10.1016/j.ijrobp.2016.06.010.CrossRefGoogle Scholar
- 18.Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, Goepfert H. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001;127:870–6.Google Scholar
- 19.Schindler A, Borghi E, Tiddia C, Ginocchio D, Felisati G, Ottaviani F. Adaptation and validation of the Italian MD Anderson dysphagia inventory (MDADI). Rev Laryngol Otol Rhinol (Bord). 2008;129:97–100.Google Scholar
- 20.CTCAE v4.0 (2016) Cancer therapy evaluation program. Division of Cancer Treatment & Diagnosis. National Cancer Institute. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 14 Nov 2016.
- 25.R Core Team (2016). R: a language and environment for statistical computation. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/. Accessed 30 Jan 2017.
- 26.Jensen K, Bonde Jensen A, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol. 2006;78:298–305. https://doi.org/10.1016/j.radonc.2006.02.005.CrossRefGoogle Scholar
- 27.Pedersen A, Wilson J, McColl E, Carding P, Patterson J. Swallowing outcome measures in head and neck cancer–How do they compare? Oral Oncol. 2016;52:104–8. https://doi.org/10.1016/j.oraloncology.2015.10.015.CrossRefGoogle Scholar
- 29.Roe JW, Drinnan MJ, Carding PN, Harrington KJ, Nutting CM. Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia? Oral Oncol. 2014;50:1182–7. https://doi.org/10.1016/j.oraloncology.2014.09.009.CrossRefGoogle Scholar
- 31.Schindler A, Denaro N, Russi EG, Pizzorni N, Bossi P, Merlotti A, Spadola Bissetti M, Numico G, Gava A, Orlandi E, Caspiani O, Buglione M, Alterio D, Bacigalupo A, De Sanctis V, Pavanato G, Ripamonti C, Merlano MC, Licitra L, Sanguineti G, Langendijk JA, Murphy B. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus. Crit Rev Oncol Hematol. 2015;96:372–84. https://doi.org/10.1016/j.critrevonc.2015.06.005.CrossRefGoogle Scholar
- 32.Samuels SE, Tao Y, Lyden T, Haxer M, Spector M, Malloy KM, Prince ME, Bradford CR, Worden FP, Schipper M, Eisbruch A. Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation. Oral Oncol. 2016;54:68–74. https://doi.org/10.1016/j.oraloncology.2015.12.001.CrossRefGoogle Scholar
- 33.Alfieri S, Ripamonti CI, Marceglia S, Orlandi E, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi R, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati LD, Licitra L, Bossi P. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. Head Neck. 2016;38:E1521–7. https://doi.org/10.1002/hed.24272.CrossRefGoogle Scholar
- 34.Vatca M, Lucas JT Jr, Laudadio J, D’Agostino RB, Waltonen JD, Sullivan CA, Rouchard-Plasser R, Matsangou M, Browne JD, Greven KM, Porosnicu M. Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. Oral Oncol. 2014;50:869–76. https://doi.org/10.1016/j.oraloncology.2014.06.010.CrossRefGoogle Scholar
- 35.Punt S, Dronkers EAC, Welters MJP, Goedemans R, Koljenović S, Bloemena E, Snijders PJ, Gorter A, van der Burg SH, Baatenburg de Jong RJ, Jordanova ES. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17 + cell frequency. Cancer Immunol Immunother. 2016;65:393–403. https://doi.org/10.1007/s00262-016-1805-x.CrossRefGoogle Scholar
- 36.Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: assessment from a phase 3 registration trial. Eur J Cancer. 2016;64:1–11. https://doi.org/10.1016/j.ejca.2016.05.008.CrossRefGoogle Scholar
- 39.Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E, PARSPORT Trial Management Group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–36. https://doi.org/10.1016/S1470-2045(10)70290-4.CrossRefGoogle Scholar
- 43.Vainshtein JM, Samuels S, Tao Y, Lyden T, Haxer M, Spector M, Schipper M, Eisbruch A. Impact of xerostomia on dysphagia after chemotherapy-intensity-modulated radiotherapy for oropharyngeal cancer: prospective longitudinal study. Head Neck. 2016;38:E1605–12. https://doi.org/10.1002/hed.24286.CrossRefGoogle Scholar
- 45.Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26:3582–9. https://doi.org/10.1200/JCO.2007.14.8841.CrossRefGoogle Scholar
- 49.Goepfert RP, Lewin JS, Barrow MP, Fuller CD, Lai SY, Song J, Hobbs BP, Gunn GB, Beadle BM, Rosenthal DI, Garden AS, Kies MS, Papadimitrakopoulou VA, Schwartz DL, Hutcheson KA. Predicting two-year longitudinal MD Anderson dysphagia inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. Laryngoscope. 2017;127:842–8. https://doi.org/10.1002/lary.26153.CrossRefGoogle Scholar
- 51.Chen AM, Li BQ, Lau DH, Farwell DG, Luu Q, Stuart K, Newman K, Purdy JA, Vijayakumar S. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2010;78:1026–32. https://doi.org/10.1016/j.ijrobp.2009.09.036.CrossRefGoogle Scholar
- 53.Paleri V, Roe JW, Strojan P, Corry J, Grégoire V, Hamoir M, Eisbruch A, Mendenhall WM, Silver CE, Rinaldo A, Takes RP, Ferlito A. Strategies to reduce long-term postchemoradiation dysphagia in patients with head and neck cancer: an evidence-based review. Head Neck. 2014;36:431–43. https://doi.org/10.1002/hed.23251.CrossRefGoogle Scholar
- 56.Cartmill B, Cornwell P, Ward E, Davidson W, Porceddu S. A prospective investigation of swallowing, nutrition, and patient-rated functional impact following altered fractionation radiotherapy with concomitant boost for oropharyngeal cancer. Dysphagia. 2012;27:32–45. https://doi.org/10.1007/s00455-011-9333-5.CrossRefGoogle Scholar